You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,239,331

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,239,331

Title:	Method for predicting the response to HER2-directed therapy
Abstract:	This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
Inventor(s):	Bacus; Sarah S. (Hinsdale, IL), Smith; Bradley L. (Marblehead, MA)
Assignee:	Ventana Medical Systems, Inc. (Tuscon, AZ) Cell Signaling Technology, Inc. (Beverly, MA)
Application Number:	14/595,825
Patent Claims:	1. A method for identifying a breast tumor likely to respond to HER-2 directed therapy, comprising measuring by in a tissue sample obtained from the breast: tumor: a) negative expression of insulin-like growth factor receptor (IGFR) polypeptide; and b) positive expression of phosphorylated S6 ribosomal polypeptide; identifying the breast tumor as a breast tumor likely to respond to HER-2 directed therapy; and administering a HER-2directed therapy to the subject from which the breast tumor sample was obtained. 2. The method of claim 1, wherein the HER2-directed therapy comprises trastuzumab. 3. The method of claim 1, wherein the tissue sample is a biopsy sample. 4. The method of claim 3, wherein the biopsy sample is a paraffin-embedded sample. 5. The method of claim 1, wherein phosphorylation of S6 ribosomal polypeptide is determined using an antibody specific for an epitope comprising a phosphorylated serine at position 235 of SEQ ID NO: 2. 6. The method of claim 1, wherein the breast tumor overexpresses HER2 polypeptide. 7. The method of claim 1, wherein the breast tumor has previously been treated with at least one chemotherapeutic. 8. The method of claim 7, wherein the at least one chemotherapeutic comprises cisplatin, doxorubicin, or taxol.

Details for Patent 9,239,331

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2022-04-05
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2022-04-05
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2022-04-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.